Virtual HDR CyberKnife SBRT for localized prostatic carcinoma: 5-year disease-free survival and toxicity observations

Frontiers in Oncology

Volumn 4, Issue NOV, 2014, Pages

  Fuller, Donald Blake ^a   Naitoh, John ^b   Mardirossian, George ^a  

^a San Diego CyberKnife Center   (United States)

^b Coast Urology Medical Group Inc   (United States)

Author keywords

Brachytherapy; CyberKnife; Dosimetry; HDR; Image guided; Prostate cancer; Stereotactic body radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CYBERKNIFE; DISEASE FREE SURVIVAL; GASTROINTESTINAL TOXICITY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROSTATE CARCINOMA; RADIATION DOSE; RECURRENCE FREE SURVIVAL; STEREOTACTIC BODY RADIATION THERAPY; UROGENITAL TRACT DISEASE;

EID: 84928316953     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00321     Document Type: Article

References (33)

1. Freeman DE, King CR. Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes. Radiat Oncol (2011) 6(1):3. doi: 10.1186/1748-717X-6-3
2. Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat (2009) 8(5):387-92. doi:10.1177/153303460900800509
3. King CR, Collins S, Fuller D, Wang PC, Kupelian P, Steinberg M, et al. Health-related quality of life after stereotactic body radiation therapy for localized prostate cancer: results from a multi-institutional consortium of prospective trials. Int J Radiat Oncol Biol Phys (2013) 87(5):939-45. doi:10.1016/j.ijrobp.2013.08.019
4. King CR, Freeman D, Kaplan I, Fuller D, Bolzicco G, Collins S, et al. Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials. Radiother Oncol (2013) 109(2):217-21. doi:10.1016/j.radonc.2013.08.030
5. McBride SM, Wong DS, Dombrowski JJ, Harkins B, Tapella P, Hanscom HN, et al. Hypofractionated stereotactic body radiotherapy in low-risk prostate adenocarcinoma: preliminary results of a multi-institutional phase 1 feasibility trial. Cancer (2012) 118(15):3681-90. doi:10.1002/cncr.26699
6. Katz AJ, Kang J. Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study. Front Oncol (2014) 4:240. doi:10.3389/fonc.2014.00240
7. Tree AC, Ostler P, Hoskin P, Dankulchai P, Nariyangadu P, Hughes RJ, et al. Prostate stereotactic body radiotherapy - first UK experience. Clin Oncol (2014). doi:10.1016/j.clon.2014.08.007
8. Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy (2014) 12(4):391-408. doi:10.1007/s40258-014-0106-9
9. Parthan A, Pruttivarasin N, Davies D, Taylor DC, Pawar V, Bijlani A, et al. Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer. Front Oncol (2012) 2:81. doi:10.3389/fonc.2012.00081
10. Demanes DJ, Martinez AA, Ghilezan M, Hill DR, Schour L, Brandt D, et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys (2011) 81(5):1286-92. doi:10.1016/j.ijrobp.2010.10.015
11. Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys (2005) 61(5):1306-16. doi:10.1016/j.ijrobp.2004.08.014
12. Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, et al. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol (2004) 171(3):1098-104. doi:10.1097/01.ju.0000113299.34404.22
13. Mate TP, Gottesman JE, Hatton J, Gribble M, Van Hollebeke L. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys (1998) 41(3):525-33. doi:10.1016/S0360-3016(98)00097-2
14. Vargas CE, Martinez AA, Boike TP, Spencer W, Goldstein N, Gustafson GS, et al. High-dose irradiation for prostate cancer via a high-dose-rate brachytherapy boost: results of a phase I to II study. Int J Radiat Oncol Biol Phys (2006) 66(2):416-23. doi:10.1016/j.ijrobp.2006.04.045
15. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol (1988) 12(12):897-906. doi:10.1097/00000478-198812000-00001
16. King CR, Lehmann J, Adler JR, Hai J. CyberKnife radiotherapy for localized prostate cancer: rationale and technical feasibility. Technol Cancer Res Treat (2003) 2(1):25-30. doi:10.1177/153303460300200104
17. Fuller DB, Naitoh J, Lee C, Hardy S, Jin H. Virtual HDR CyberKnife treatment for localized prostatic carcinoma: dosimetry comparison with HDR brachytherapy and preliminary clinical observations. Int J Radiat Oncol Biol Phys (2008) 70(5):1588-97. doi:10.1016/j.ijrobp.2007.11.067
18. Virtual HDR. CyberKnife Radiosurgery for Localized Prostatic Carcinoma: A Phase II Study. NCT01045148. Available from: http://www.clinicaltrials.gov/
19. CyberKnife Radiosurgery For Low & Intermediate Risk Prostate Cancer: Emulating HDR Brachytherapy Dosimetry. NCT00643617. Available from: http://www.clinicaltrials.gov/
20. Demanes DJ, Altieri G, Barnaba M. High dose rate (HDR) monotherapy is equivalent to combined HDR brachytherapy and external beam radiation therapy (EBRT) for early prostate cancer. Int J Radiat Oncol Biol Phys (2006) 66:S351. doi:10.5114/jcb.2013.37942
21. Villers A, McNeal JE, Freiha FS, Boccon-Gibod L, Stamey TA. Invasion of Denonvilliers' fascia in radical prostatectomy specimens. J Urol (1993) 149(4):793-8.
22. Chao KK, Goldstein NS, Yan D, Vargas CE, Ghilezan MI, Korman HJ, et al. Clinicopathologic analysis of extracapsular extension in prostate cancer: should the clinical target volume be expanded posterolaterally to account for microscopic extension? Int J Radiat Oncol Biol Phys (2006) 65(4):999-1007. doi:10.1016/j.ijrobp.2006.02.039
23. Martinez AA, Pataki I, Edmundson G, Sebastian E, Brabbins D, Gustafson G. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report. Int J Radiat Oncol Biol Phys (2001) 49(1):61-9. doi:10.1016/S0360-3016(00)01463-2
24. Zelefsky MJ, Yamada Y, Pei X, Hunt M, Cohen G, Zhang Z, et al. Comparison of tumor control and toxicity outcomes of high-dose intensity-modulated radiotherapy and brachytherapy for patients with favorable risk prostate cancer. Urology (2011) 77(4):986-90. doi:10.1016/j.urology.2010.07.539
25. Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys (2007) 67(4):1099-105. doi:10.1016/j.ijrobp.2006.10.050
26. Ko EC, Stone NN, Stock RG. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure. Int J Radiat Oncol Biol Phys (2012) 83(2):600-7. doi:10.1016/j.ijrobp.2011.07.009
27. Zelefsky MJ, Shi W, Yamada Y, Kollmeier MA, Cox B, Park J, et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys (2009) 75(5):1350-6. doi:10.1016/j.ijrobp.2008.12.067
28. Zagars GK. Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy. Int J Radiat Oncol Biol Phys (1992) 23(1):47-53. doi:10.1016/0360-3016(92)90542-P
29. Barkati M, Williams SG, Foroudi F, Tai KH, Chander S, van Dyk S, et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: a phase II trial. Int J Radiat Oncol Biol Phys (2012) 82(5):1889-96. doi:10.1016/j.ijrobp.2010.09.006
30. Le Fur E, Malhaire JP, Nowak E, Rousseau B, Erauso A, Pene-Baverez D, et al. Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation. Brachytherapy (2013) 12(6):589-95. doi:10.1016/j.brachy.2013.04.002
31. Roeloffzen EM, Crook J, Monninkhof EM, McLean M, van Vulpen M, Saibishkumar EP. External validation of the pretreatment nomogram to predict acute urinary retention after (125)I prostate brachytherapy. Brachytherapy (2012) 11(4):256-64. doi:10.1016/j.brachy.2011.12.011
32. King CR, Brooks JD, Gill H, Presti JC Jr. Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys (2012) 82(2):877-82. doi:10.1016/j.ijrobp.2010.11.054
33. Fuller DB, Shirazi R, Naitoh J, Mardirossian G. Virtual HDR SBRT for localized prostatic carcinoma: efficacy and quality of life assessment. Int J Radiat Oncol Biol Phys (2011) 81(2):S423-4. doi:10.1016/j.ijrobp.2011.06.694